News from 2013

eZono 4000 with needle guidance approved in Europe

eZono 4000 with needle guidance approved in Europe

Xention partners its lead atrial fibrillation drug with Servier

Xention and Servier announce a cardiovascular collaboration to further develop a selective Kv1.5 modulator for the treatment of atrial fibrillation

Alliance Pharma acquires global rights to Syntometrine from Novartis

Alliance Pharma plc has acquired all existing rights to SyntometrineTM from Novartis AG and Novartis Pharma AG (together "Novartis") for a consideration of US$11.5 million.

Graham Cox to join eZono as CEO

eZono’s supervisory board has appointed Graham D. Cox as the company’s Chief Executive Officer effective 1st June 2013. Mr. Cox will succeed Allan R. Dunbar, co-founder and acting CEO of eZono, who remains with the company as Chief Commercial Officer.

Cara partners with Maruishi for Japanese rights to CR845

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca

Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.

Biovex Phase III trial meets primary endpoint

Biovex’s acquirer Amgen announces Phase III trial of talimogene laherparepvec in melanoma has met its primary endpoint

U.S. FDA Approval of Lombard's Aorfix

MVM portfolio company Lombard Medical Technology announces the US Food and Drug Administration ("FDA")approves its stent graft, Aorfix.

Heptares announces deal with Cubist

Heptares Therapeutics has announced that it has signed an agreement with Cubist Pharmaceuticals, Inc (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs).